Case Reports

POEMS syndrome: a significant clinical response to lenalidomide


 

POEMS syndrome is a rare paraneoplastic syndrome whose cause is unknown. In this case of POEMS syndrome, the patient showed significant clinical improvement after treatment with lenalidomide. Of note is that although polyneuropathy is a known side effect of IMiDs, lenalidomide is an immune modulator that is cytotoxic to malignant plasma cells but has a much lower risk of peripheral neuropathy.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Experimental quizartinib gives bridge to transplant in relapsed AML
MDedge Hematology and Oncology
Targeting new myeloma pathway pays off with ARRY-520
MDedge Hematology and Oncology
FDA approves ponatinib for CML and Ph-positive ALL
MDedge Hematology and Oncology
Chemo-free combo tames 'worst of the worst' acute leukemia
MDedge Hematology and Oncology
TOPPS: Limit prophylactic platelets to select groups
MDedge Hematology and Oncology
Double-unit cord blood transplants don't boost survival
MDedge Hematology and Oncology
Live from ASH: Dr. David Henry shares his 'did you know' picks
MDedge Hematology and Oncology
Did you know: Dr. David Henry reports from ASH
MDedge Hematology and Oncology
Experimental CARS therapy breaks through relapsed CLL
MDedge Hematology and Oncology
Imatinib approved for children with Ph+ acute lymphoblastic leukemia
MDedge Hematology and Oncology